

BIOTRONIK Home Monitoring®



Maximum Reliability Due to Unique Monitoring Technology

Home Monitoring device
T device with RF antenna




- Automatic data transmission
- Daily data transmission, including event IEGMs
- Improved diagnostics with up to 4 IEGMs in daily data transmission¹
- Notification of transmission gaps
- Minimum energy consumption of the daily data transmission²

Mobile transmitter
CardioMessenger Smart




- Easy initialization thanks to plug & play set-up
- Automatic pairing of implanted device and CardioMessenger
- Worldwide data transmission via mobile phone network
- Full patient mobility with battery life of up to 48 h³

Online platform
Home Monitoring Service Center



- Automatic data transfer in case of implanted device replacement
- Configuration of monitoring parameters directly on the BIOTRONIK Home Monitoring platform
- Patient-specific event reports
- Event prioritization through intelligent traffic light system


Industry-leading transmission reliability with BIOTRONIK Home Monitoring^{4,5}



BIOTRONIK Home Monitoring

Efficient Remote Follow-Up with BIOTRONIK Home Monitoring


BIOTRONIK Home Monitoring can safely replace in-office follow-ups. Patient-oriented remote follow-up spares unnecessary visits to the doctor and improves patient adherence.²



Reliable Early Detection with BIOTRONIK Home Monitoring

Continuous monitoring allows early detection of technically and clinically relevant events and prompt intervention.²

- Reduction of all-cause mortality risk in heart failure patients⁶
- Fewer patients with worsening heart failure status⁶
- Reduction of inadequate shocks⁷
- Fewer hospitalizations due to atrial fibrillation, strokes and inadequate shock deliveries^{7,8}



1 As of Inlexa/Intica. 2 Varma N et al.; The TRUST trial. *Circulation* 2010; 122:325-332; doi: 10.1161/CIRCULATIONAHA.110.937409. 3 CardioMessenger Smart. 4 Varma N et al.; *Europace Journal* 2011; 13(3): Abstract P1026. 5 Crossley G H et al.; The Connect trial. *Journal of the American College of Cardiology* 2011; 54 (10): 1181-1189. 6 Hindricks G et al.; IN-TIME study. *The Lancet* 2014; 384(9943). 7 Guedón-Moreau L et al.; ECOST study *European Heart Journal* 2012. doi: 10.1161/CIRCEP.110.951962. 8 Mabo P et al.; The COMPAS trial. *European Heart Journal* 2011, doi: 10.1093/eurheartj/ehr419.